A nationwide study of serous “borderline” ovarian tumors in Denmark 1978–2002: centralized pathology review and overall survival compared with the general population
BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors
Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver
Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas
Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas
Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants
The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study
Tumor repressor protein 53 and steroid hormones provide a new paradigm for ovarian cancer metastases
Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary
Previous
Previous
2015
Next
Next